ICUIHealthcare · Medical Instruments & SuppliesThe 8 Wall Street analysts covering ICU Medical, Inc. hold a median 12-month price target of $193 — +5.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores ICU Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (97): Analysts have, on balance, been raising their forecasts.
Growth (57): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (26): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ICUI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +5.2% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | BTIG | Maintains | Buy | $170 → $200 |
| 7 Aug 2026 | Needham | Maintains | Buy | $165 → $187 |
| 7 Aug 2026 | Piper Sandler | Maintains | Overweight | $163 → $195 |
| 21 July 2026 | Keybanc | Maintains | Overweight | $164 → $182 |
| 21 July 2026 | Keybanc | Maintains | Overweight | — |
| 15 June 2026 | BTIG | Initiates | Buy | — |
| 15 June 2026 | BTIG | Initiates | Buy | $170 |
| 27 May 2026 | Needham | Upgrade | Buy | — |
| 27 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 17 Apr 2026 | Piper Sandler | Maintains | Overweight | — |
| 20 Feb 2026 | Keybanc | Maintains | Overweight | — |
| 20 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 7 Nov 2025 | Keybanc | Maintains | Overweight | — |
| 7 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
| 21 Oct 2025 | Keybanc | Maintains | Overweight | — |
| 10 Sept 2025 | Piper Sandler | Maintains | Overweight | — |
| 15 Aug 2025 | Piper Sandler | Initiates | Overweight | — |
| 8 Aug 2025 | Raymond James | Maintains | Strong Buy | — |
| 9 May 2025 | Raymond James | Maintains | Strong Buy | — |
| 21 Apr 2025 | Keybanc | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ICUI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 5% of US stocks
Cheaper than 52% of US stocks
Cheaper than 45% of US stocks
Cheaper than 22% of US stocks
Higher than 29% of US stocks
Higher than 11% of US stocks
Higher than 54% of US stocks
Higher than 65% of US stocks
Higher than 50% of US stocks
Higher than 46% of US stocks
Higher than 60% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ICU Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ICU Medical (NASDAQ:ICUI) reported upbeat earnings for the second quarter on Thursday. Following the results, analysts boosted their forecasts for the company.
Why it matters — The upbeat second-quarter results and ensuing analyst forecast increases signal improving sentiment around ICU Medical's recent performance.
ICU Medical, Inc. held its Q2 2026 earnings call, and the full transcript of the call has been published on Seeking Alpha. The item provides a record of the company's second-quarter 2026 conference call.
Why it matters — An ICUI watcher would care because the earnings call transcript contains management's commentary on the company's quarterly results and outlook.
ICU Medical reported second-quarter revenue of $548 million, up 6% organically and 1% on a reported basis. Growth in its consumables and infusion systems businesses helped offset continued pressure in Vital Care and the effects of the IV Solutions joint venture deconsolidation.
Why it matters — The earnings call highlights organic growth in core businesses while noting ongoing headwinds in Vital Care and the deconsolidation of the IV Solutions joint venture, giving ICUI watchers a factual picture of current performance drivers.
ICU Medical reported its earnings for the quarter ended June 2026. The article notes that its top- and bottom-line figures, along with other key metrics, can be compared against Wall Street estimates and year-ago values.
Why it matters — A ICU Medical watcher would care because this review of its Q2 metrics offers insight into how the company's quarterly performance compares with analyst expectations and prior-year results.
ICU Medical reported quarterly earnings of $2.37 per share, exceeding the Zacks Consensus Estimate of $1.91 per share and up from $2.10 per share a year ago, while also topping revenue estimates.
Why it matters — The company beat analyst earnings expectations for the quarter, signaling stronger-than-anticipated performance for those following ICU Medical.
The 8 Wall Street analysts covering ICU Medical, Inc. have a median 12-month price target of $193, with estimates ranging from $178 to $210. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering ICU Medical, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ICU Medical, Inc. 96 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, ICU Medical, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +5.2% from the last close, and Ticker Nerd's factor model ranks ICU Medical, Inc. 96 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ICU Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICUI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $178 to $210 over the next 12 months.
ICU Medical, Inc. returned +63.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
ICU Medical Inc. is a medical technology company that develops, manufactures, and sells innovative medical devices for infusion therapy, vascular access, and vital care applications worldwide.
The most recent item we track (Benzinga, 7 Aug 2026): "ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings". ICU Medical (NASDAQ:ICUI) reported upbeat earnings for the second quarter on Thursday. Following the results, analysts boosted their forecasts for the company.
ICU Medical Inc. is a medical technology company that develops, manufactures, and sells innovative medical devices for infusion therapy, vascular access, and vital care applications worldwide. Its product portfolio spans three key business segments: Consumables, featuring infusion sets, vascular access products, and specialty chemicals; Infusion Systems, including ambulatory, syringe, and large volume IV pumps with safety software, dedicated and non-dedicated IV sets, needle-free connectors, and informatics services; and Vital Care, offering hemodynamic monitoring, temperature management, airway management, and pain kits. Notable products include needlefree connectors under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock and ChemoClave closed system transfer devices for hazardous drugs; Tego needle-free connectors; Deltec GRIPPER non-coring needles; and various IV therapy solutions like sodium chloride, dextrose, and irrigation products. ICU Medical Inc. serves acute care hospitals, ambulatory clinics, alternate site facilities, and home care settings through direct sales, independent distributors, and partnerships, with a global presence across the U.S., Europe, Asia-Pacific, Middle East, Africa, and other regions. Founded in 1984 and headquartered in San Clemente, California, it plays a critical role in enhancing patient safety, preventing bloodstream infections, and protecting healthcare workers from hazardous exposures in the medical devices sector.
CEO Mr. Vivek Jain · 13,000 employees · United States · https://www.icumed.com